<div id="readability-page-1"><div>Overview<ul><li>Sensei Biotherapeutics reports Q3 net loss of $4.6 mln, down from $7.3 mln last year</li><li>Company reduces workforce by 65% to preserve cash</li></ul>Outlook<ul><li>Sensei Biotherapeutics exploring strategic alternatives, including asset sales and potential merger</li><li>Company implements workforce reduction to preserve cash amid strategic review</li><li>Sensei retains small team for compliance and strategic exploration</li></ul>Result Drivers<ul><li>WORKFORCE REDUCTION - Sensei reduced its workforce by approximately 65% to preserve cash amid strategic review</li><li>R&amp;D expenses were $2.5 million for the quarter ended September 30, 2025, compared to $4.6 million for the quarter ended September 30, 2024</li></ul>Key Details<div><table><tbody><tr><td>Metric</td><td>Beat/Miss</td><td>Actual</td><td>Consensus Estimate</td></tr><tr><td>Q3 EPS</td><td></td><td>-$3.62</td><td></td></tr><tr><td>Q3 Net Income</td><td></td><td>-$4.57 mln</td><td></td></tr><tr><td>Q3 Income From Operations</td><td></td><td>-$4.85 mln</td><td></td></tr><tr><td>Q3 Operating Expenses</td><td></td><td>$4.85 mln</td><td></td></tr></tbody></table></div>Analyst Coverage<ul><li>The current average analyst rating on the shares is &#34;buy&#34; and the breakdown of recommendations is 1 &#34;strong buy&#34; or &#34;buy&#34;, 1 &#34;hold&#34; and no &#34;sell&#34; or &#34;strong sell&#34;</li><li>The average consensus recommendation for the biotechnology &amp; medical research peer group is &#34;buy&#34;</li></ul>Press Release: For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</div></div>

SNSE

Sensei Biotherapeutics reported a Q3 net loss of $4.6 million, down from $7.3 million last year. The company reduced its workforce by 65% to preserve cash amid a strategic review, which includes exploring asset sales and potential mergers. R&D expenses decreased to $2.5 million from $4.6 million. The average analyst rating for the company is "buy."

Sensei Biotherapeutics Q3 loss narrows; reduces workforce by 65%